Cytomos Overview

Founded 2012
Status Private
Employees 1
Latest Deal Type Early Stage VC
Latest Deal Amount $2.13M
Latest Deal Amount
Investors 2

Cytomos General Information


Developer of a medical diagnostics technology designed to assist in label-free cell analysis for biomedical research. The company's patented cell analysis technology ensures that every cell is analysed providing granular information on individual cells and the whole sample population, facilitates automated and quantitative sample assessment, phenotypic drug discovery and stem cell therapy, enabling medical researchers to find functional end points that conventional assays cannot reach and generate high-content fingerprints to select the right dose for the right patients, thereby making cell-based diagnostics quicker and simpler.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Primary Office
  • 13 Melville Street
  • Edinburgh EH3 7PE
  • Scotland, United Kingdom
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytomos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 23-Apr-2018 $2.13M 00.000 00.000 Completed Startup
2. Early Stage VC 16-Feb-2016 00000 00000 00.000 Completed Startup
1. Angel (individual) 15-Dec-2014 $157K $157K 00000 Completed Startup

Cytomos Cap Table

To view Cytomos‘s complete cap table, request access >>
Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 19,800 $0.000014 $7.14 $7.14 1x $7.14 4.78%

Cytomos Executive Team (1)

Name Title Board Seat Contact Info
Keith Muir Ph.D Founder & Chief Executive Officer

Cytomos Board Members (3)

Name Representing Role Since
Alister Minty Self Chairman 000 0000
Gino Miele Ph.D Self Board Member 000 0000
Margaret Temple Self Board Member 000 0000

Cytomos Investors (2)

To view Cytomos‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Scottish Enterprise Venture Capital Minority 000 0000 000000 0
Archangel Investors Angel Group Minority 000 0000 000000 0

Ready to get started?

Request a free trial